Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
Preprint
- 3 May 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material and methods: We studied 30 years outcome of 4124 postmenopausal patients who were randomized to receive (totally) two or five years of adjuvant tamoxifen. Results: After 5 years of follow-up, when tamoxifen treatment was finished in both groups, until 15 years of follow-up, overall mortality (HR 0.80, 95% CI 0.72 – 0.90, p< 0.001), breast cancer mortality for all patients (HR 0.80, 95% CI 0.68 – 0.94, p= 0.006) and breast cancer mortality for patients with estrogen receptor positive disease (HR 0.67, 95% CI 0.55 – 0.83, p< 0.001) were significantly reduced in the five-year group as compared to the two-year group. After 15 years, the difference remained but did not further increase. In the five-year group, the incidence of contralateral breast cancer was gradually reduced during the entire period of observation. The incidence of lung cancer was also reduced in the five-year group. In contrast there was an increased endometrial cancer incidence in the five-year group and for those receiving 40 mg of tamoxifen this incidence was further increased. Conclusion: Three more years of tamoxifen therapy reduced the risk of breast cancer mortality. The difference was established during the first 15 years after randomization. Moreover, the incidence of contralateral breast cancer gradually decreased for 30 years. The incidence of lung cancer was reduced in the five-year group. In contrast the incidence of endometrial cancer was increased.Keywords
All Related Versions
- Version 1, 2023-05-03, Research Square
- Published version: The Breast, 71, 63.
This publication has 20 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trialBritish Journal of Cancer, 2011
- Lung cancer mortality risk among breast cancer patients treated with anti‐estrogensCancer, 2011
- Menopausal hormone therapy and risk of lung cancer—Systematic review and meta-analysisMaturitas, 2010
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancerActa Oncologica, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast CancerJNCI: Journal of the National Cancer Institute, 1996
- Long-Term Effects of Adjuvant Tamoxifen and/or Radiotherapy: The South Sweden Breast Cancer TrialActa Oncologica, 1992
- ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERSThe Lancet, 1989